• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    12/29/22 8:07:46 AM ET
    $BDTX
    $BXRX
    $DERM
    $DNAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $BDTX alert in real time by email

    Gainers

    • Quotient (NASDAQ:QTNT) stock moved upwards by 114.0% to $0.49 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 million.
    • Baudax Bio (NASDAQ:BXRX) shares increased by 84.34% to $4.24. The market value of their outstanding shares is at $2.3 million.
    • Kala Pharmaceuticals (NASDAQ:KALA) shares increased by 49.19% to $18.62. The market value of their outstanding shares is at $29.7 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock moved upwards by 27.85% to $0.78. The company's market cap stands at $10.1 million.
    • Journey Medical (NASDAQ:DERM) shares increased by 20.33% to $1.42. The company's market cap stands at $25.1 million.
    • Nuwellis (NASDAQ:NUWE) stock rose 19.95% to $11.0. The company's market cap stands at $3.4 million.

    Losers

    • Exicure (NASDAQ:XCUR) shares fell 11.2% to $1.03 during Thursday's pre-market session. The company's market cap stands at $5.1 million.
    • Vaxxinity (NASDAQ:VAXX) shares declined by 7.98% to $1.27. The market value of their outstanding shares is at $160.0 million.
    • Codex DNA (NASDAQ:DNAY) shares decreased by 7.44% to $1.12. The company's market cap stands at $33.0 million.
    • Unicycive Therapeutics (NASDAQ:UNCY) shares fell 7.0% to $0.47. The company's market cap stands at $7.0 million.
    • Relmada Therapeutics (NASDAQ:RLMD) stock decreased by 6.26% to $3.0. The market value of their outstanding shares is at $90.2 million.
    • Black Diamond Therapeutic (NASDAQ:BDTX) stock decreased by 6.19% to $1.54. The company's market cap stands at $55.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BDTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDTX
    $BXRX
    $DERM
    $DNAY

    CompanyDatePrice TargetRatingAnalyst
    Relmada Therapeutics Inc.
    $RLMD
    1/23/2026$8.00Outperform
    Leerink Partners
    Relmada Therapeutics Inc.
    $RLMD
    12/22/2025$69.00Buy
    Jefferies
    Black Diamond Therapeutics Inc.
    $BDTX
    12/3/2025Buy → Neutral
    Guggenheim
    Relmada Therapeutics Inc.
    $RLMD
    11/19/2025$10.00Neutral → Outperform
    Mizuho
    Black Diamond Therapeutics Inc.
    $BDTX
    11/18/2025$9.00Overweight
    Piper Sandler
    Black Diamond Therapeutics Inc.
    $BDTX
    10/16/2025$8.00Buy
    Stifel
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $BDTX
    $BXRX
    $DERM
    $DNAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Traversa Sergio bought $113,300 worth of shares (27,500 units at $4.12), increasing direct ownership by 2% to 1,300,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:49 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shenouda Maged bought $48,060 worth of shares (11,665 units at $4.12), increasing direct ownership by 1% to 800,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:24 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Kelly Paul Edward bought $198,000 worth of shares (90,000 units at $2.20), increasing direct ownership by 22% to 502,295 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    11/6/25 7:30:02 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDTX
    $BXRX
    $DERM
    $DNAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 3% to 301 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    2/19/26 2:27:21 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Schultz Carisa

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    2/12/26 4:15:30 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Field Katharyn

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    2/11/26 3:35:38 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BDTX
    $BXRX
    $DERM
    $DNAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders

    Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week, signaling a potential shift in how regulators and investors view psychedelic-based psychiatry[1]. The pathway is widening at the federal level, where the Drug Enforcement Administration raised its 2026 psilocybin production quota by 67%[2]. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), Relmada Therapeutics (NASDAQ:RLMD), Alto Neuroscience (NYSE:ANRO), and Axsome

    2/26/26 12:07:00 PM ET
    $ANRO
    $AXSM
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BDTX
    $BXRX
    $DERM
    $DNAY
    SEC Filings

    View All

    Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    2/26/26 8:49:40 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    2/23/26 8:10:39 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by KALA BIO Inc.

    8-K - KALA BIO, Inc. (0001479419) (Filer)

    2/20/26 4:05:55 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDTX
    $BXRX
    $DERM
    $DNAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners resumed coverage on Relmada Therapeutics with a new price target

    Leerink Partners resumed coverage of Relmada Therapeutics with a rating of Outperform and set a new price target of $8.00

    1/23/26 8:21:07 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Relmada Therapeutics with a new price target

    Jefferies initiated coverage of Relmada Therapeutics with a rating of Buy and set a new price target of $69.00

    12/22/25 8:39:56 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Black Diamond Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Black Diamond Therapeutics from Buy to Neutral

    12/3/25 12:43:23 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BDTX
    $BXRX
    $DERM
    $DNAY
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

    Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to datePFS data for 1L NSCLC patients expected in Q2 2026; Company continues to explore partnership opportunities for pivotal development of silevertinibBased on encouraging CNS activity of silevertinib in multiple trials across NSCLC and GBM, Company plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed GBM patients in 1H 2026; initial data anticipated in 2028Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025;

    12/3/25 7:01:00 AM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

    Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two independent paths for approval in two separate NMIBC indications: High-risk 2nd line BCG-unresponsive, and Intermediate-risk patients in the adjuvant setting; Studies expected to begin H1 2026 Completed $100M underwritten offering of common stock and pre-funded warrants on November 5th to support planned operations into 2028 Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NAS

    11/13/25 4:01:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDTX
    $BXRX
    $DERM
    $DNAY
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Announces Changes to Board of Directors

    MINNEAPOLIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced the appointment of Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026. Ms. Field is the Chief Executive Officer of ISpecimen Inc., where she oversees performance improvement and the redevelopment of the proprietary software platform. Prior to serving as Chief Executive Officer she served as President, Chairman, and as an independent director. She has served as a director of LogProstyle since September 2024, as an Executive Director of Akanda Corporation since Ju

    1/23/26 4:40:27 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BDTX
    $BXRX
    $DERM
    $DNAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care